**Introduction**

**Rationale for review**

As the at-risk population including older, diabetic, dialysis-dependent and intravenous drug user patients has increased, so has the incidence of IE (1). Invasive procedures leading to bacteremia are ubiquitous in modern medicine (2). Improved survival among patients with congenital cardiac anomalies and an increasing number of patients with implantable prostheses are likely to contribute to the rise in IE as well (1). Hospitalization related to IE has indeed increased between 2000 and 2011 (1) (Figure 1).

The opioid epidemic merits special attention, with approximately 10% of Americans using an illicit drug according to the National Survey on Drug Use and Health (4). The estimated number of heroin users in 2016 was higher than the number for all years between 2002 and 2013 (4). Over the last five decades, increasing numbers of IE are being attributed to intravenous drug use (IVDU) (5). IVDUs are comprising an increasing percentage of patients requiring surgery as well (6) (Figure 2). IVDU is unique not only because of its role in the causation of IE, but because of the recidivism and reinfection that is common among drug users. There is no consensus among surgeons about

---

**Abstract:** The number of hospitalizations and surgical cases of infective endocarditis (IE) are increasing. The aim of this study was to review these trends, surgical outcomes, and controversies related to IE. A search of MEDLINE of studies published between 1960 and 2018 was conducted. Search terms included “infective endocarditis”, “history of”, “trend”, “epidemiology”, “outcome”, “medical management”, “surgery”, “indication”, and “re-operative surgery”, or any combination thereof. The United States has the highest incidence of IE in the world at 15 per 100,000 people, with increases in incidence due to the aging population as well as increasing rates of intravenous drug use (IVDU). National guidelines support early surgical intervention in specific clinical settings in both left and right-sided IE. However, only 11% of the evidence used in formulating guidelines for surgical therapy in IE are based on level A evidence. Ongoing controversies include whether to perform surgery in the setting of continued or recurrent IVDU in a patient with a prior valve operation, timing of surgery after acute stroke due to IE, and general indications for surgery for tricuspid valve IE. IE has a surging incidence and increasing burden on the healthcare system in the United States. Multiple controversies exist, and formulating level A evidence and multidisciplinary collaboration will be essential components to effectively treating this complex patient population.

**Keywords:** Infective endocarditis (IE); surgery; outcomes; trends; controversies

Submitted Apr 30, 2019. Accepted for publication Jul 24, 2019.

doi: 10.21037/jtd.2019.10.45

**View this article at:** http://dx.doi.org/10.21037/jtd.2019.10.45
how to treat patients with an ongoing addiction problem.

Besides the controversies regarding IE in drug users, multiple aspects regarding the surgical management of this condition are uncertain. The aim of this review is to provide an up-to-date summary of trends, surgical outcomes, and controversies in IE.

**Materials and methods**

A search was conducted on MEDLINE of studies in English language published between January 1, 1960, and March 1, 2019. The search terms included “infective endocarditis”, “history of”, “trend”, “epidemiology”, “outcome”, “medical management”, “surgery”, “indication”, and “re-operative surgery” or any combination thereof. All types of articles were included. The bibliography was further augmented by references found in the articles retrieved from MEDLINE.

**Results**

**Trends in infective endocarditis**

In the United States, the incidence of IE was 15 per 100,000 people in 2011 and has continued to increase (1,3,7-9). Several decades ago, most cases of IE in the U.S. were in the setting of rheumatic heart disease, which is still the case in many developing countries (6). Current trends
indicate that growth of the aging population with medical comorbidities and their associated interactions with the healthcare system are likely to contribute to the increasing incidence of IE (10-12). Patients with pre-existing cardiac valve replacements, implants or indwelling catheters rose by 42% during 1998–2009 (7). Also noted was the increase in endocarditis related to IVDU (5).

Although the characteristics of the disease have changed significantly, the in-hospital and 6-month mortality still approaches 18% and 30%, respectively (13,14).

In a population-based study, the distribution of causative organisms, namely Streptococci viridans, Staphylococci, Enterococci, and HACEK did not change during 1970 through 2006, with Streptococcus predominating with a range of 30–50% (15). From 2007 to 2013, Staphylococcus aureus led the group, comprising 33% of IE, with Streptococcus viridans dropping to 16% (16). Nationally, valve replacement rates paralleled the rising incidence of IE until 2007. In the year 2000, the valve replacement rate was 11 per 100,000 population, which increased to 30 in the year 2007. Between 2007 and 2011, the rates remained stable (1).

In a review of the global burden of IE, the United States was found to have the highest incidence whereas the Netherlands reported the lowest (11.6 vs. 1.5 cases respectively per 100,000) (17). Patients with IE in the United States also had a higher prevalence of diabetes, hemodialysis and the highest prevalence of chronic intravenous access, demonstrating a striking association with health-care-related IE (13). Staphylococcus aureus was the most common causative organism of IE globally (10,18).

**Medical management of infective endocarditis**

Most cases of IE are treated medically (Table 1). IE from Methicillin Sensitive Staphylococcus Aureus (MSSA) responds better to oxacillin than vancomycin, indicating the need for de-escalation of antibiotics once the organism is identified (20). Daptomycin appears to be equally effective as vancomycin plus gentamicin for Staphylococcus aureus bacteremia with or without definite IE (21). Ceftriaxone alone for Streptococcal IE and ceftriaxone plus ampicillin for Enterococcal IE are adequate treatments (19,22,23). Combination therapy with gentamicin has very little additional benefit compared to its higher toxicity profile (19,23).

**Indications for surgery in infective endocarditis**

Several national and international bodies have published the indications for surgery in IE (Table 2) (24-29) with severe heart failure being the most common one (24-26,28,29). However, there has been a shift in the timing of surgery for IE with preference for earlier intervention. A recent randomized clinical trial compared early surgery within 48 hours to delayed surgery at any time during the remainder of the hospitalization or follow-up (30). Those undergoing early surgery had a reduced composite rate of death, embolic event, or recurrence of IE at 6 months (3% versus 28%) (30). In a recent meta-analysis, among propensity-matched cohorts of patients with IE, surgery within the first 7 days was associated with a lower risk of mortality (31). Although not popularized immediately, early surgery is being adopted into practice with the median interval between admission and surgery being 4 days in some case series (32,33).

**Surgical techniques & outcomes**

The most important principle of surgery for IE is aggressive debridement and removal of any and all infected tissue. Attention is paid to disrupt the ‘inoculum effect’, where large concentrations of bacteria reside in biofilms, secluded from antibiotics (34). Treatment for aortic valve IE can include valve repair or replacement, or root reconstruction, with multiple options existing for the latter (29). Our group is aggressive in treating any involvement of the aortic root, and have recently published our experience with 138
Table 1 Select studies describing the medical management of infective endocarditis

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Study design, number of cases, follow up period</th>
<th>Organisms involved</th>
<th>Valves involved</th>
<th>Antibiotics evaluated</th>
<th>Outcome</th>
<th>Surgery rate</th>
<th>Complications</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sexton et al. (19)</td>
<td>1998</td>
<td>Randomized, multicenter, open-label study, 61 patients followed up to 3 months</td>
<td>Penicillin susceptible streptococci</td>
<td>Native left sided valves with acquired and congenital abnormalities</td>
<td>2 g ceftriaxone daily for 4 weeks vs. combination therapy with 2 g ceftriaxone and 3 mg/kg of gentamicin daily for 2 weeks</td>
<td>Clinical and microbiological cure rate approximately 96% in both groups without any relapse</td>
<td>36% vs. 19.2% in combination vs. monotherapy. RR for surgery 1.87 (95% CI, 0.73–4.82).</td>
<td>Fever, GI upset and elevation of creatinine in the combination group</td>
<td>No patients discontinued therapy for side effects</td>
</tr>
<tr>
<td>Fortun et al. (20)</td>
<td>2001</td>
<td>RCT, 31 patients with IVDU followed for 30 months</td>
<td>Methicillin susceptible Staphylococcus aureus</td>
<td>Tricuspid valve</td>
<td>Cloxacillin vs. vancomycin vs. teicoplanin</td>
<td>No deaths, 100% cure with oxacillin, 60% with vancomycin, 70% with teicoplanin</td>
<td>None</td>
<td>Teicoplanin associated with rash, neutropenia</td>
<td>62–73% HIV positive, 1 clinical failure and 2 relapses in teicoplanin group</td>
</tr>
<tr>
<td>Fowler et al. (21)</td>
<td>2006</td>
<td>RCT, 246 patients with S. aureus bacteremia with or without IE followed for 42 days</td>
<td>Staphylococcus aureus, MRSA</td>
<td>Tricuspid valve</td>
<td>Daptomycin vs. gentamicin and anti-staph penicillin or vancomycin</td>
<td>Success (no clinical, microbiological failure or death) was 42.7% with daptomycin and 39.3% with standard therapy</td>
<td>One on each arm</td>
<td>Drug related adverse effect between 2.5–5.2%</td>
<td>38% in both groups had MRSA, 75% had either definite or possible IE as baseline diagnosis</td>
</tr>
</tbody>
</table>

IE, infective endocarditis; MRSA, Methicillin resistant Staphylococcus aureus; RCT, randomized controlled trial.
patients with endocarditis of the aortic root undergoing replacement with cryopreserved homograft (35). These patients had a high-risk profile with 61.6% undergoing reoperative sternotomy, and 48.5% having severe aortic insufficiency. The operative mortality rate was 12.3%, with a stroke rate of 3.6%, indicating that cryopreserved homograft replacement of the aortic root in these complex cases is safe and desirable. These are challenging operations and an analysis of the STS database involving over 11,000 patients demonstrated an increased risk-adjusted mortality for root replacements, particularly for homografts as compared to valve replacements (Table 3) (33). Operative

Table 2 Indications for surgery in infective endocarditis according to the 2014 American College of Cardiology/American Heart Association and the 2015 European Society of Cardiology guidelines

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Valve dysfunction resulting in symptoms of HF</td>
<td>(I) Heart failure</td>
<td>Emergency</td>
</tr>
<tr>
<td>Aortic or mitral NVE or PVE with severe acute regurgitation, obstruction or fistula causing refractory pulmonary edema or cardiogenic shock</td>
<td>Urgent</td>
<td></td>
</tr>
<tr>
<td>Aortic or mitral NVE or PVE with severe regurgitation or obstruction causing symptoms of HF or echocardiographic signs of poor hemodynamic tolerance</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(II) Uncontrolled infection</td>
<td>Abscess, false aneurysm, fistula, enlarging vegetation</td>
<td>Urgent</td>
</tr>
<tr>
<td>Heart block, annular or aortic abscess, or destructive penetrating lesions</td>
<td>Fungi or multi-resistant organism</td>
<td>Urgent/elective</td>
</tr>
<tr>
<td>Left-sided IE caused by Staphylococcal aureus, fungal, or other highly resistant organisms</td>
<td>Persisting positive blood cultures despite appropriate antibiotic therapy and adequate control of septic metastatic foci</td>
<td>Urgent</td>
</tr>
<tr>
<td>Persistent infection: persistent bacteremia or fevers &gt;5 to 7 days after appropriate antimicrobial therapy</td>
<td>PVE caused by staphylococci or non-HACEK gram-negative bacteria</td>
<td>Urgent/elective</td>
</tr>
<tr>
<td>PVE and relapsing infection</td>
<td>Recurrent emboli and persistent vegetations despite appropriate antibiotic therapy</td>
<td>Urgent</td>
</tr>
<tr>
<td>Aortic or mitral NVE or PVE with persistent vegetations &gt;10 mm after one or more embolic episode despite appropriate antibiotic therapy</td>
<td>Urgent</td>
<td></td>
</tr>
<tr>
<td>Aortic or mitral NVE with vegetations &gt;10 mm, associated with severe valve stenosis or regurgitation, and low operative risk</td>
<td></td>
<td></td>
</tr>
<tr>
<td>NVE with mobile vegetations &gt;10 mm with or without clinical evidence of embolic phenomenon</td>
<td>Aortic or mitral NVE or PVE with isolated very large vegetations (&gt;30 mm) (Class Ila)</td>
<td>Urgent</td>
</tr>
<tr>
<td>Aortic or mitral NVE or PVE with isolated large vegetations (&gt;15 mm) and no other indication for surgery (Class IIb)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right sided NVE</td>
<td>Microorganisms difficult to eradicate (e.g., fungi) or bacteremia &gt;7 days despite antibiotics</td>
<td></td>
</tr>
<tr>
<td>Persistent tricuspid vegetation &gt;20 mm after recurrent pulmonary emboli with or without HF</td>
<td>Right heart failure from severe tricuspid regurgitation with poor response to diuresis</td>
<td></td>
</tr>
</tbody>
</table>

NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; AV, aortic valve; MV, mitral valve; HF, heart failure.
<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>Design, use of database, study period, valve evaluated</th>
<th>Patient and operative profile</th>
<th>Method of reconstruction</th>
<th>Outcome</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Savage et al.</td>
<td>2014</td>
<td>Retrospective, STS ACSD, 2005–2011, primary (n=8,421) and re-operative (n=3,139) cases of IE involving the aortic valve undergoing mechanical vs. stented biologic vs. homografts</td>
<td>Biologic patients were older with more DM, HLD, HTN, Class III/IV HF</td>
<td>Valve replacement, vs. root replacement with valve conduit vs. other (repair, root without valve etc.)</td>
<td>Adjusted mortality higher in root replacement compared to valve replacement (OR 1.43). Homografts worse mortality compared to biologic (OR 1.37). Unadjusted mortality for primary vs. re-operative: 9.8 vs. 21.1%</td>
<td>Use of biologic increasing over time across all cases, with mechanical and homograft decreasing in both primary and re-operative cases. Homografts used mostly in re-operations</td>
</tr>
<tr>
<td>Mayer et al.</td>
<td>2011</td>
<td>Retrospective, single institution, 2000–2009, 100 cases of aortic IE</td>
<td>31 cases in ICU preoperatively. Replacement patients older with significantly higher EuroSCORE. CBP and cross-clamp time similar</td>
<td>Repair (33%) vs. replacement (67%) (biologic, mechanical, Ross)</td>
<td>Early mortality and morbidity similar (9% vs. 18%, P=0.37). Survival at 4 years better after repair (44% vs. 65% P=0.047). Re-operation more frequent after repair (only in &gt;1 cm patches)</td>
<td>AR more frequent in repair than replacement (P=0.066)</td>
</tr>
<tr>
<td>Kim et al.</td>
<td>2016</td>
<td>Retrospective propensity-matched, 2 tertiary referral institutions, 2002–2014, 304 adults with active IE</td>
<td>Xenograft patients oldest followed by homograft and mechanical. DM, smoking and class III/IV HF similar</td>
<td>Homograft (28.3%) vs. mechanical (26%) vs. xenograft (45.7%)</td>
<td>After risk adjustment, early (19.8% vs. 12.7% vs. 7.2%) &amp; long-term mortality (26.7% vs. 19.0% vs. 15.8%) or valve-related complications similar. Homograft did not affect reinfection rate</td>
<td>Risk factor for early &amp; late mortality: IDDM, elevated Cr, MRSA, multivalve IE, PVE, IABP, and root replacement. Risk factor for reinfection: current IVDU, multivalve IE, severe valvular dysfunction. Homograft not associated with reinfection</td>
</tr>
<tr>
<td>Lee et al.</td>
<td>2018</td>
<td>Retrospective, Taiwanese national research database, 2000–2013, 1,999 cases of MV surgery for IE, 352 propensity-matched patients in the final analysis</td>
<td>Repair vs. replacement had similar baseline characteristics</td>
<td>MV replacement (78.8%) vs. repair (21.2%)</td>
<td>Repair had lower in-hospital mortality (6.3% vs. 10.8%. P=0.031), lower late mortality (HR 0.67, 95% CI, 0.52–0.7), fewer strokes, transfusions</td>
<td>The beneficial effect of repair was less apparent in hospitals with low volume. Among patients with active IE, MV repair had lower all-cause mortality</td>
</tr>
</tbody>
</table>

STS, society of thoracic surgeons; ACDS, adult cardiac surgery database; IE, infective endocarditis; DM, diabetes mellitus; HLD, hyperlipidemia; HTN, hypertension; HF, heart failure; OR, odds ratio; CBP, cardio-pulmonary bypass; NVE, native valve endocarditis; PVE, prosthetic valve endocarditis; IDDM, insulin-dependent DM; IABP, intra-aortic balloon pump; MV, mitral valve.
mortality was substantially higher in reoperative cases (21.1% versus 9.8%). Another study evaluating specific types of root replacement demonstrated no differences in early and long-term mortality between homografts, xenografts, and mechanical ones (37).

In the mitral position, the benefits of repair when technically feasible have been documented in retrospective studies (Table 3) (29). A study of 352 propensity-matched cohorts comparing mitral repair versus replacement demonstrated lower in-hospital mortality, fewer strokes, lower transfusion rates, and improved long-term survival with repair (38). Double valve involvement requires complex operations and is associated with poorer outcomes (Table 3) (39). An analysis of 25 cases requiring double valve replacements demonstrated a 30-day mortality of 32% (39).

**Controversies**

**Surgery for infective endocarditis in the intravenous drug user**

An analysis of 78 active IVDUs and 358 non-IVDUs from a prospectively maintained database between 2002 and 2014 showed that the 30-day mortality after surgery was lower for IVDUs at 3.8% compared to 13.7% for non-IVDUs, attributable to their lower surgical risk profile (40). Among IVDUs, valve re-infection (37% by a median of 18 months) was significantly higher compared to non-IVDUs, as was the reoperation rate. In another single-institution study between 1999 and 2010, outcomes of 64 IVDUs were compared to 133 non-IVDUs (41). The pattern of valve involvement was similar with a predominance of left-sided disease in both groups. Although freedom from reoperation was similar, IVDU was an independent risk factor for diminished survival. Recurrent IE was more common among IVDUs (12.5% vs. 2.3%). Redo sternotomy had a mortality of 12.5% in this cohort (41). Among the medically managed cases in these two studies, half had prohibitive risk for surgery despite meeting indications, and died of their disease. Despite the reported variation in short term outcomes, long-term survival between users and non-users are not different (40,42,43). Neither is compliance in follow up (40,41).

The most challenging aspect in IVDU related IE is the underlying addiction. The long-term mortality in these patients are not only related to IE, but also to violence or drug overdose (44). There is no consensus among the surgeons regarding management of this critical underlying issue. Intensive rehabilitation program among patients with IE starting as inpatients is reported with reasonable success rates (45,46).

Given the scarcity of data, much of the decision-making regarding surgery in drug abusers is individualized and reflects the opinions of providers and institutions. Poor outcomes, risking exposure to the operating team, challenging reconstructive operations, and the elevated risk of returning to drug use are all reasons for not operating on these patients (47). At the same time, refusing to operate can be challenged from a legal and ethical standpoint. Some have argued that physicians should not venture into the moral background of a recidivist patient (47,48). They have likened recurrent IE from drug-addiction to recurrent cancer where treatment would not be refused. This often leads to debate and confusion amongst the various disciplines caring for IVDU patients with IE. These issues are most relevant in the setting of reoperative surgery in the recidivist IVDU.

**Timing of surgery after acute stroke due to infective endocarditis**

An ischemic insult to the brain leaves a penumbra of tissue which is potentially salvageable by careful critical care management (49). Cardiopulmonary bypass and systemic anticoagulation may extend the penumbra or result in a hemorrhagic conversion. On the other hand, early surgery reduces further embolization and may prevent further valvular destruction (30).

In a study of 243 patients having surgery for IE, one third of whom had a preoperative stroke, the rate of new postoperative stroke or mortality was not different among patients with or without a preoperative stroke (50). In another retrospective review of 137 patients with non-severe stroke, surgery within 2 weeks of onset of neurological symptoms was associated with a significant benefit in reducing IE-related death (22% vs. 61%, P<0.001) (51). Despite these findings, delayed or no cardiac surgery after stroke remains a widespread clinical practice largely owing to worsening clinical status (52).

In our practice, operations are performed early, usually within 2 weeks in patients with relatively well-preserved neurologic exam and without a large deficit or hemorrhagic component on brain imaging. For those patients with a significant clinical deficit or radiological finding, we typically will delay surgery for 4–6 weeks followed by a repeat assessment. In either case, digital subtraction angiography is essential for ruling out mycotic aneurysms which can be fatal if surgery is pursued.
Indications for surgery in tricuspid valve infective endocarditis

In general, tricuspid valve surgery is recommended in patients who have severe tricuspid regurgitation with or without symptomatic heart failure while undergoing surgery for left-sided valvulopathy (24). In endocarditis, although size and mobility of vegetations are the most important indicators of embolism or mortality for left sided diseases, the indications for operation for the right side of the heart are not very clear (53,54). Predominantly based on retrospective data, the European Society of Cardiology (ESC) task force for the management of IE recommends surgery for vegetations greater than 20 mm after recurrent emboli regardless of the presence of heart failure (25,55,56). Other indications include microorganisms that are difficult to eradicate, persistent bacteremia and severe right-sided heart failure with poor response to diuretics. In cases where there is concomitant left-sided endocarditis, atrial septal defect, infected indwelling catheters, pacing leads and prosthetic valve endocarditis, early surgery may be considered (57,58). The American Heart Association (AHA) and the American Association of Thoracic Surgery (AATS) have endorsed these indications (29,34).

Septic embolization to the lung itself is not an indication for operation in the absence of large vegetations (25). In a retrospective study of 40 patients with septic pulmonary embolism, only 27% of them were related to IE. None of these patients were treated with cardiac surgery, and most responded to antibiotics with or without pleural drainage (59). In a systemic review, among 168 cases of septic pulmonary embolism, only 7 patients required valve surgery (60). Regardless, septic embolization is one of the most commonly quoted reasons for tricuspid intervention (61).

The debate between replacement versus repair of the tricuspid valve for IE is much better informed (61-63). In a retrospective analysis of 366 patients undergoing tricuspid valve surgery, 30-day mortality after tricuspid valve repair was 14%, compared to 33% for replacement (P<0.001). The 10-year survival was also improved for tricuspid valve repair with a tendency towards greater freedom from reoperation (61). On the other hand, a propensity-matched analysis of 315 patients and a recent meta-analysis did not find any difference in operative mortality or long-term survival for replacement versus repair (61,63). However, valve repair was associated with lower recurrence of IE, lower need for reoperation, and a lower need for permanent pacemakers (61).

Our approach to tricuspid valve IE has been to operate in cases of large vegetations over 20 mm particularly if associated with recurrent pulmonary emboli, persistent bacteremia, or severe valvular insufficiency. In cases where the vegetations are smaller, we typically employ a period of medical management with intravenous antibiotics, followed by re-evaluation. In addition, we ensure that any other undrained areas of infections, such as an empyema, are addressed before open-heart surgery. We have anecdotally found that operating under cardiopulmonary bypass in the setting of compromised lungs, either from infection or septic embolization, frequently leads to poor oxygenation requiring extracorporeal support. Thorough drainage of the lung space and supportive care, with amelioration of respiratory failure are therefore essential prerequisites for successful lung recovery after cardiac surgery.

Conclusions

Only 11% of the evidence used in formulating guidelines for the surgical management of IE are from level A studies (64). The need for formulating level A evidence through national and international collaboration is well recognized (65). With surging numbers of IE, the unchecked opioid epidemic, and ever-increasing contact with the healthcare system, this need may soon become a dire necessity. Effective collaboration between specialties, namely cardiac surgery, cardiology, critical care, infectious disease, ethics, as well as primary care is imperative in the establishment of consensus for treating this complex patient population.

Acknowledgments

None.

Footnotes

Conflicts of Interests: Thomas Gleason: Medical Advisory Board, Abbott (Chicago, IL, USA). Arman Kilic: Medical Advisory Board, Medtronic, Inc. (Minneapolis, MN, USA). University of Pittsburgh Medical Center Heart and Vascular Institute receives research support from Medtronic, Abbott, and Boston Scientific (Marlborough, MA, USA). The other authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

References


